Synjardy XR

Synjardy XR · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 20, 2026

166 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (96)

Dec 11, 2034patentUS 9949998*PED
Dec 11, 2034patentUS 9949998*PED
Dec 11, 2034patentUS 9949998*PED
Dec 11, 2034patentUS 9949998*PED
Nov 17, 2034patentUS 9949997*PED
Nov 17, 2034patentUS 9949997*PED
Nov 17, 2034patentUS 9949997*PED
Nov 17, 2034patentUS 9949997*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11813275*PED
Oct 3, 2034patentUS 11813275*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 12433906*PED
Oct 3, 2034patentUS 12433906*PED
Oct 3, 2034patentUS 12433906*PED
Oct 3, 2034patentUS 12433906*PED
Jun 11, 2034method-of-use (U-2290)US 9949998
Jun 11, 2034method-of-use (U-2290)US 9949998
Jun 11, 2034method-of-use (U-2290)US 9949998
Jun 11, 2034method-of-use (U-2290)US 9949998
May 17, 2034method-of-use (U-3533)US 9949997
May 17, 2034method-of-use (U-3533)US 9949997
May 17, 2034method-of-use (U-3533)US 9949997
May 17, 2034method-of-use (U-3533)US 9949997
Apr 3, 2034method-of-use (U-2290)US 10258637
Apr 3, 2034method-of-use (U-2290)US 10258637
Apr 3, 2034method-of-use (U-2290)US 10258637
Apr 3, 2034method-of-use (U-2290)US 10258637
Apr 3, 2034method-of-use (U-3193)US 11090323
Apr 3, 2034method-of-use (U-3193)US 11090323
Apr 3, 2034method-of-use (U-3193)US 11090323
Apr 3, 2034method-of-use (U-3193)US 11090323
Apr 3, 2034method-of-use (U-4154)US 11666590
Apr 3, 2034method-of-use (U-4154)US 11666590
Apr 3, 2034method-of-use (U-4154)US 11666590
Apr 3, 2034method-of-use (U-4154)US 11666590
Apr 3, 2034method-of-use (U-3759)US 11813275
Apr 3, 2034method-of-use (U-3759)US 11813275
Apr 3, 2034method-of-use (U-3776)US 11833166
Apr 3, 2034method-of-use (U-3776)US 11833166
Apr 3, 2034method-of-use (U-3777)US 11833166
Apr 3, 2034method-of-use (U-3776)US 11833166
Apr 3, 2034method-of-use (U-4154)US 12263153
Apr 3, 2034method-of-use (U-4154)US 12263153
Apr 3, 2034method-of-use (U-4154)US 12263153
Apr 3, 2034method-of-use (U-4154)US 12263153
Apr 3, 2034method-of-use (U-4287)US 12427162
Apr 3, 2034method-of-use (U-4287)US 12427162
Apr 3, 2034method-of-use (U-4287)US 12427162
Apr 3, 2034method-of-use (U-4287)US 12427162
Apr 3, 2034method-of-use (U-4296)US 12433906
Apr 3, 2034method-of-use (U-4294)US 12433906
Apr 3, 2034method-of-use (U-4294)US 12433906
Apr 3, 2034method-of-use (U-4296)US 12433906
Sep 7, 2032patentUS 10596120*PED
Sep 7, 2032patentUS 10596120*PED
Sep 7, 2032patentUS 10596120*PED
Sep 7, 2032patentUS 10596120*PED
Mar 7, 2032formulationUS 10596120
Mar 7, 2032formulationUS 10596120
Mar 7, 2032formulationUS 10596120
Mar 7, 2032formulationUS 10596120
Aug 11, 2030patentUS 12115179*PED4.1y
Aug 11, 2030patentUS 12115179*PED4.1y
Aug 11, 2030patentUS 12115179*PED4.1y
Aug 11, 2030patentUS 12115179*PED4.1y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Feb 1, 2029patentUS 7579449*PED2.6y
Feb 1, 2029patentUS 7579449*PED2.6y
Feb 1, 2029patentUS 7579449*PED2.6y
Feb 1, 2029patentUS 7579449*PED2.6y
Aug 1, 2028compositionUS 75794492.1y
Aug 1, 2028compositionUS 75794492.1y
Aug 1, 2028compositionUS 75794492.1y
Aug 1, 2028compositionUS 75794492.1y
Oct 15, 2027patentUS 7713938*PED1.3y
Oct 15, 2027patentUS 7713938*PED1.3y
Oct 15, 2027patentUS 7713938*PED1.3y
Oct 15, 2027patentUS 7713938*PED1.3y
Apr 15, 2027compositionUS 7713938282d
Apr 15, 2027compositionUS 7713938282d
Apr 15, 2027compositionUS 7713938282d
Apr 15, 2027compositionUS 7713938282d

FDA exclusivities (8)

Dec 20, 2026PEDPediatric (6mo bonus)166d
Dec 20, 2026PEDPediatric (6mo bonus)166d
Dec 20, 2026PEDPediatric (6mo bonus)166d
Dec 20, 2026PEDPediatric (6mo bonus)166d
Jun 20, 2026M-296Method (3y)
Jun 20, 2026M-296Method (3y)
Jun 20, 2026

(empagliflozin + metformin hydrochloride ER)

indications

all catalysts(15)

News(0)

comments(0)

Report a data issue

Patent cliff

patents (96)

FDA exclusivities (8)

🐶 often sniffed alongside